Intratracheal Administration of Recombinant Human Factor IX (BeneFix™) Achieves Therapeutic Levels in Hemophilia B Dogs

Summary

The purpose of this paper was to establish proof of concept for administration of human recombinant F.IX (rF.IX) by inhalation for therapy of hemophilia B. The pharmacokinetics of intratracheal (IT) administration of rF.IX was studied in nine hemophilia B dogs randomized into 3 groups that received 200 IU/kg IT, 1000 IU/kg IT, or 200 IU/kg intravenously (IV). IT rF.IX produced therapeutic levels of F.IX antigen and activity and the pharmacokinetic parameters were consistent with a slow release from a depot site within the lungs. Bio-availability compared to IV administration was 11% for 200 IU/kg IT and 4.9% for 1000 IU/kg. The whole blood clotting time began to shorten at 2 h but F.IX bioactivity was not detected until 8 h post infusion in both IT groups. In all groups, F.IX activity was detected through 72 h post administration. These data demonstrate that biologically active rF.IX can reach the systemic circulation when given IT. Aerosolization of rF.IX may provide a needle-free therapeutic option for delivery of rF.IX to hemophilia B patients.

Key words

Factor IX - hemophilia B - inhalation therapy

• References

• 1 Liles D, Landen CN, Monroe DM, Lindley CM, Read MS, Roberts HR, Brinkhous KM. Extravascular administration of factor IX: Potential for replacement therapy of canine and human hemophilia B. Thromb Haemost 1997; 77: 944-8.
• 2 Patton JS, Platz RM. Pulmonary delivery of peptides and proteins for systemic action. Adv Drug Del Rev 1992; 8: 179-96.
• 3 Hubbard RC, Casolaro MA, Mitchell M, Sellers SE, Arabia F, Matthay MA, Crystal RG. Fate of aerosolized recombinant DNA-produced alpha1-antitrypsin: Use of epithelial surface of the lower respiratory tract to administer proteins of therapeutic importance. Proc Natl Acad Sci 1989; 86: 680-4.
• 4 Brinkhous KM, Sigman JL, Read MS, Stewart PF, McCarthy KP, Timony GA, Leppanen SD, Rup BJ, Keith Jr JC, Schaub RG. Recombinant human factor IX: Replacement therapy prophylaxis pharmacokinetics, and immunogenicity in canine hemophilia B. Blood 1996; 88: 2603-10.
• 5 Russel KE, Nichols TC, Elwell DR, Bellinger DA, Raymer RA, McElveen PR, Rup BJ, Keith JC, Leitermann K, McCarthy KP, Schaub RG, Read MS. Intratracheal administration of recombinant human factor IX (Benefix™) achieves therapeutic levels. Blood 1998; 92: 356a.
• 6 Evans JP, Brinkhous KM, Brayer GD, Reisner HM, High KA. Canine Hemophilia, B resulting from a point mutation with unusual consequences. Proc Natl Acad Sci USA 1989; 86: 10095-9.
• 7 Kay MA, Rothenberg S, Landen CN, Bellinger DA, Leland F, Toman C, Finegold M, Thompson AR, Read MS, Brinkhous KM, Woo SLC. In vivo gene therapy of hemophilia B: Sustained partial correction in factor IX-deficient dogs. Science 1993; 262: 117-9.
• 8 Herzog R, Arruda VR, Fischer TH, Read MS, Nichols TC, High KA. Absence of circulating factor IX antigen in hemophilia B dogs of the UNC-Chapel Hill Colony. Thromb Haemost 2000; 84: 352-4.
• 9 Harrison S, Clancy B, Brodeur S, Oaks P, Miller D, Drapeau D, Hamilton M, Charlebois T, Leonard M, McCarthy M, Zollner R, Adamson SR. Development of a serum-free process for recombinant factor IX expression in Chinese hamster ovary cells. Thromb Haemost 1995; 73: 1222.
• 10 Foster WB, Anagnostopoulos A, Bonam D, Costigan RJ, Knight A, Sterl KS, Switzer MB, Walsh RE. Development of a process for purification of recombinant human factor IX. Blood 1995; 86: 870a.
• 11 Rodriques H, Giles K, Sefton L, Griffon V, Duxbury M, Letwin B. Analytical characterization of recombinant human factor IX: Pharamacokinetic studies in the rat and the dog. Thromb Haemost 1995; 73: 1206.
• 12 Keith Jr JC, Ferranti TJ, Misra B, Frederick T, Rup B, McCarthy K, Faulkner R, Bush L, Schaub RG. Evaluation of recombinant human factor IX: Pharmacokinetic studies in the rat and the dog. Thromb Haemost 1994; 73: 101-5.
• 13 Lee RI, White PD. A clinical study of the coagulation time of blood. Am J Med Sci 1913; 145: 495-503.
• 14 Brinkhous KM, Landen CN, Read MS. Evaluation of sensitivity of whole blood clotting time (WBCT), partial thromboplastin time (PTT), and F. IX one-stage bioassay tests with low plasma F. IX levels observed with transfusion or gene therapy in canine hemophilia B. Blood 1993; 82 (Suppl. 01) 592a.
• 15 Mustafa RL, Elwell DR, Russell KE, Nichols TC, Read MS. A role for whole blood clotting time as a sensitive screening test for F. VIII and F. IX replacement. Blood 1998; 92: 96b.
• 16 Pedersen PV. Novel Deconvolution Method for Linear Pharmacokinetic Systems with Polyexponential Impulse Response. J Pharm Sci 1980; 69: 312-8.
• 17 Gerrard AJ, Austen DEG, Brownlee GG. Subcutaneous injection of factor IX for the treatment of haemophilia B. British Journal of Haematology 1992; 81: 610-3.
• 18 McCarthy KP, Timony GA, Ferranti TJ, Misra BR, Keith Jr JC, Bree AG, Schleman FJ, Resmini C, Haire TC, Schaub RG, Garzone PD. Subcutaneous bioavailability of recombinant factor IX (BeneFix^™) in healthy beagle dogs and cynomolugus monkeys. Blood 1996; 88: 68b.
• 19 Cheung WF, van den Born J, Kuhn K, Kjellen L, Hudson BG, Stafford DW. Identification of the endothelial cell binding site for factor IX. Proc Natl Acad Sci USA 1996; 93: 11068-73.
• 20 Wolberg AS, Stafford DW, Erie DA. Human factor IX binds to specific sites on the collagenous domain of collagen IV. J Biol Chem 1997; 272: 16717-20.
• 21 Brinkhous KM, Sigman JL, Read MS, Stewart PF, Bush L, Bartlett E, Rup B, Keith Jr JC, Garzone P, McCarthy K, Schaub RG. Subcutaneous recombinant factor IX (BeneFIX™) administration produces therapeutic levels of FIX activity in hemophilia B dogs. Blood 1996; 88: 422a.
• 22 Yu J, Chien YW. Pulmonary drug delivery: Physiologic and mechanistic aspects. Crit Rev Therap Drug Carr Sys 1997; 14: 395-453.
• 23 Brain JD, Knudson DE, Sorokin SP, Davis MA. Pulmonary distribution of particles given by intratracheal instillation or by aerosol inhalation. Environ Res 1976; 11: 13-33.
• 24 Colthorpe P, Farr SJ, Taylor G, Smith IJ, Wyatt D. The pharmacokinetics of pulmonary-delivered insulin: A comparison of intratracheal and aerosol administration to the rabbit. Pharm Res 1992; 9: 764-8.
• 25 Gillespie MN, Krechniak JW, Crooks PA, Altiere RJ, Olson JW. Pulmonary metabolism of exogenous enkephalins in isolated perfused rat lungs. J Pharmacol Exp Ther 1985; 232: 675-8.
• 26 Jendle J, Karlberg BE, Persliden J, Franzen L, Arborelius M. Delivery and retention of an insulin aerosol produced by a new jet nebulizer. J Aersol Med 1995; 8: 243-54.
• 27 Jendle JH, Karlberg BE, Arborelius M. An exploration of intrapulmonary insulin administration in anaesthetized and mechanically ventilated pigs. Scand J Clin Lab Invest 1996; 56: 251-8.
• 28 Laube BL, Georgopoulos A, Adams GK. Preliminary study of the efficacy of insulin aerosol delivered by oral inhalation in diabetic patients. JAMA 1993; 269: 2106-9.
• 29 Gupta S, Moussy F, Dalby RN, Miekka SI, Bruley DF. Pulmonary delivery of human protein C and factor IX. in (ed) NaL (ed) Oxygen Transport to Tissue XVIII. New York: Plenum Press; 1997. p 429-35.
• 30 Wigley FM, Londono JH, Wood SH, Shipp JC, Waldman RH. Insulin across respiratory mucosae by aerosol delivery. Diabetes 1971; 20: 552-6.